Toxicology Profile of a Novel GLP-1 Receptor Agonist

Glucagon‐like peptide‐1 (GLP-1) receptor agonists have emerged as promising therapeutic options for addressing type‐2 diabetes, obesity, and related conditions. However, because of the continued need for injectable administration, many GLP-1 agonists face compliance challenges. To improve the design and production of GLP-1 receptor biased agonists with enhanced druggability, a novel small molecule, designated SAL0112, was developed.

WuXi AppTec recently contributed to a study which characterized the toxicology profile of this molecule.  SAL0112 demonstrated a favorable safety profile in NHPs, with a substantial therapeutic window that supports the progression of this compound into clinical studies.